OTCMKTS:LBTSF Almirall (LBTSF) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free LBTSF Stock Alerts $9.51 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$9.51▼$9.5150-Day Range$9.51▼$9.5152-Week Range$8.85▼$10.18VolumeN/AAverage Volume200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Almirall alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Almirall Stock (OTCMKTS:LBTSF)Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.Read More LBTSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LBTSF Stock News HeadlinesMay 13, 2024 | marketwatch.comAlmirall Shares Rise After Confirmed Targets, Revenue IncreaseFebruary 20, 2024 | msn.comAlmirall, S.A. reports FY resultsFebruary 19, 2024 | finance.yahoo.comAlmirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology businessFebruary 5, 2024 | msn.comAlmirall and Microsoft partner on AI-powered drug discovery in dermatologyDecember 12, 2023 | marketwatch.comAlmirall, Etherna Team Up to Develop MRNA-Based Dermatology TherapiesDecember 12, 2023 | finance.yahoo.comAlmirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical DermatologyNovember 17, 2023 | marketwatch.comAlmirall Shares Rise on European Approval for Skin DrugNovember 17, 2023 | finance.yahoo.comAlmirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic DermatitisNovember 15, 2023 | msn.comAlmirall and Absci partner on AI-driven dermatological drug developmentNovember 14, 2023 | finanznachrichten.deAbsci Corporation: Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseasesNovember 14, 2023 | finance.yahoo.comAlmirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseasesNovember 14, 2023 | msn.comAbsci, Almirall partner on dermatologic drug developmentNovember 9, 2023 | msn.comAlmirall, S.A. reports 9M resultsNovember 9, 2023 | businesswire.comAlmirall’s Nine-month 2023 Results:October 13, 2023 | businesswire.comAlmirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for CyclosporineOctober 12, 2023 | msn.comAlmirall and EpimAb partner to develop bispecific antibody therapiesOctober 12, 2023 | businesswire.comEpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License AgreementOctober 11, 2023 | finance.yahoo.comAlmirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque PsoriasisOctober 10, 2023 | businesswire.comCentrient Pharmaceuticals joins Almirall’s growing innovation hub in BarcelonaSeptember 18, 2023 | msn.comEMA’s CHMP supports Almirall’s Ebyglyss for atopic dermatitisJuly 24, 2023 | msn.comAlmirall, S.A. reports 1H resultsJuly 7, 2023 | finance.yahoo.comAlmirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasisJune 13, 2023 | finance.yahoo.comAlmirall announces the pricing and closing of its €200mm non pre-emptive share capital increaseMay 8, 2023 | news.yahoo.comAlmirall's Q1 core earnings beat estimates on Europe dermatology operationsMay 8, 2023 | finance.yahoo.comAlmirall’s First Quarter 2023 ResultsSee More Headlines Receive LBTSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Almirall and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:LBTSF CUSIPN/A CIKN/A Webwww.almirall.com Phone34 93 291 30 00FaxN/AEmployees1,904Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Carlos Gallardo Piqué (Age 52)CEO, President, Member of Management Board & Chairman of the Board Comp: $54.31kMr. Michael McClellan (Age 52)CFO & Member of Management Board Mr. Eloi Crespo CerveraChief Industrial Operations Officer & Member of Management BoardMr. Esteve Conesa PanicotChief People & Culture Officer and Member of Management BoardDr. Volker KoscielnyChief Medical Officer & Member of Management BoardDr. Karl ZiegelbauerChief Scientific Officer & Member of Management BoardMr. Paolo CioniniChief Commercial Officer Europe & International and Member of Management BoardMs. Isabel Cristina GomesCompany Vice Secretary,Chief Legal Officer, General Counsel & Member of Management BoardMs. Mercedes Diz LopezChief Marketing Officer & Member of Management BoardMr. Pablo Divasson del FraileSenior Director of Investor RelationsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors LBTSF Stock Analysis - Frequently Asked Questions How have LBTSF shares performed in 2024? Almirall's stock was trading at $9.10 at the beginning of 2024. Since then, LBTSF stock has increased by 4.5% and is now trading at $9.51. View the best growth stocks for 2024 here. Are investors shorting Almirall? Almirall saw a drop in short interest in April. As of April 30th, there was short interest totaling 84,500 shares, a drop of 6.6% from the April 15th total of 90,500 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. View Almirall's Short Interest. How do I buy shares of Almirall? Shares of LBTSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:LBTSF) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Almirall, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Almirall With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.